Program Strategies to Reduce Post- Partum Hemorrhage and Pre- Eclampsia/Eclampsia: A practical review of research findings John Varallo, Khatidja Naithani, & Rehana Gubin on behalf of the MCHIP Maternal Health Team Lunchtime Roundtable CORE Group Spring Meeting 2013 1
34
Embed
Program Strategies to Reduce Post-Partum Hemorrhage and Pre-Eclampsia_John Varallo_Khatidja Naithani_Rehana Gubin_4.24.13
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Program Strategies to Reduce Post-Partum Hemorrhage and Pre-Eclampsia/Eclampsia: A practical review of research findings
John Varallo, Khatidja Naithani, & Rehana Gubinon behalf of the MCHIP Maternal Health Team
Lunchtime RoundtableCORE Group Spring Meeting 2013
1
Integrative reviews on PPH and PE/E recently published in BMC Pregnancy & Childbirth
Side effects of magnesium sulfate for PE/E management
3
IS MgSO4 A DANGEROUS DRUG?
What is PE/E?
Pre-eclampsia / eclampsia (PE/E) is a life-threatening multisystem disorder
A common cause of maternal and perinatal morbidity and mortality 9% of maternal deaths in Asia / Africa 25% of maternal deaths in Latin America / Caribbean
Global focus on prevention, detection and management strategies Expansion of use of MgSO4
4
Magnesium sulfate (MgSO4)
Drug of choice for prevention and management of eclamptic seizures
5
Significantly more effective than diazepam or phenytoin in preventing seizures in PE/E MCETG, Magpie, Cochrane
Use re-affirmed in WHO Clinical Guidelines 2011
However…
Universal and consistent use of MgSO4 has been very slow to take hold
6
Fear that MgSO4 is highly toxic
“We all know of many cases of death due to MgSO4 overdose.”
“We mustn’t let lower level workers use it due to toxicity”
“Hospitals and facilities should have calcium gluconate available to manage overdose”
“Magnesium sulfate is a dangerous drug!”
7
Potential Side Effects of MgSO4
Minor - feeling of warmth, flushing, nausea and vomiting, muscle weakness, somnolence, dizziness, and irritation at the injection site
More serious Loss of patellar reflex (typically at a serum
concentration of >8 -10 mEq/L) Respiratory depression (>15 mEq/L)
8
Research Questions Incidences of side effects of absent
patellar reflex and respiratory depression?
Frequency of use of Ca++ gluconate to counteract the effects of MgSO4 in response to detected side effects?
9
Frequency of skipped or delayed doses of MgSO4 in response to development of side effects?
How many maternal deaths of women with severe PE/E have been reported to be attributed to toxicity of MgSO4 rather than from manifestations of the underlying disease?
Results Overview
Overall Outcome Rates all studies in 9556 subjects
Affected Patella Reflex
Respiratory Depression
Oliguria Skipped Dose
Calcium Gluconate
use
Incidence 1.6% 1.3% 2.5% 3.6% 0.2%
One maternal death reported by authors as due to MgSO4
10
Results: Maternal death attributed to MgSO4
0.01% 1 / 9556 women in all groups Total maternal deaths (all causes) 91 / 9556Authors reported that cause was severe respiratory depression.
Woman’s serum magnesium was 24 mEq/L, which is well above therapeutic level
Death reported in small trial with 54 participants Magpie trial (n= 5055) had no deaths
11
Estimates of clinical impact
Affected Patellar Reflex
Respiratory depression
Skipped or delayed dose
Calcium gluconate use
Incidence 1.6% 1.3% 3.6% 0.18%NNH: Number needed to harm
61 77 27 555
Scenario: Hospital delivers 5000 women annually. Assuming 5% rate of PE/E, 250 women annually will require MgSO4 in treatment
Frequency of 1 case
2.9 months 3.7 months 1.3 months 26.7 months
12
Routine Monitoring of MgSO4 Use
Neurologic status (level of alertness and patellar reflexes)
Respiratory rate Urinary output (Oliguria is element of disease
process) Typical management of more serious side
effects: ↑ monitoring, delay next dose or suspend MgSO4 therapy, counteraction with calcium gluconate
13
14
Monitoring of MgSO4 Use
Conclusions: MgSO4 is a safe drug
Findings indicate: Low incidence of severe side effects (1-2%) When adverse effects occur, delaying the next scheduled dose is generally sufficient to mitigate the effect. Maternal mortality directly attributable to use of MgSO4 was extremely rare.
15
MgSO4 is NOT a dangerous drug
Conclusions: Policy and Practice
Severe PE/E should be diagnosed and treated with appropriate drugs, MgSO4 is anticonvulsant of choice
Women under treatment with MgSO4 need reasonable vigilance for side effects Simple protocols should be in place to manage
side effects All clinical leaders in maternal health should guide
adoption / use of MgSO4 as standard of care Including ensuring adequate supply of MgSO4
16
Community-based distribution of misoprostol for PPH prevention
26
Photo: Save the Children
What is PPH?
Blood loss >500mL in the first 24 hours after delivery
Severe PPH is loss of 1000mL or more.
Accurately quantifying blood loss is difficult in most clinical or home settings.
Many severely anemic women cannot tolerate even 500 mL blood loss
PPH: Leading Cause of Maternal Mortality
Hemorrhage is a leading cause of maternal deaths 35% of global
maternal deaths estimated 132,000
maternal deaths 14 million women in
developing countries experience PPH—26 women every minute
34%
31%
21%
0%
5%
10%
15%
20%
25%
30%
35%
40%
Africa Asia Latin America & theCaribbean
Sources: Khan et al., 2006; POPPHI, 2009; Taking Stock of Maternal, Newborn and Child Survival, 2000–2010 Decade Report
PPH Prevention
1. Active management of the third stage of labor (AMTSL) During deliveries with a skilled provider Prevents immediate PPH Associated with almost 60% reduction in PPH
occurrence1. Misoprostol
During home births without a skilled provider Community-based counseling and distribution of
misoprostol
Global Context
Inclusion on 2011 WHO Essential Drug List
Qualifications in 2012 WHO Recommendations “If a skilled attendant is not present, and
oxytocin is not available (such as at an unattended home birth), lay health workers should administer 600 mcg of oral misoprostol.”
“There is insufficient evidence to recommend the antenatal distribution of misoprostol to pregnant women for self-administration for the prevention of PPH.”
Evidentiary Gaps
2012 Cochrane review noted need for more information on:
Feasibility of misoprostol reaching the end-user (coverage)
Patient outcomes after use Adverse effects from misuse Outcomes useful to
policymakers, such as resource utilization
Research Questions
What is the range of implementation strategies for programs distributing misoprostol for the prevention of PPH at home births?
Which strategies achieve high distribution and coverage rates?
Do misoprostol programs adversely affect facility birth rates?
What is the incidence of adverse outcomes for misoprostol users, especially of mistimed administration before birth?
12,615 were followed-up Results presented based on
number of women on whom condition was reported (i. e . , d a ta is inc o m p le te )
Results Overview
34
When was misoprostol distributed?
Timing of Distribution # programs
(n =18)% of
programs
Any antenatal care visit (>12 weeks) 4 22.2%
Late pregnancy home visit (28–32 weeks) 4 22.2%
Late pregnancy antenatal care visit (>28 weeks) 3 16.7%
At home birth 10 55.6%
35
Who distributed the misoprostol?
Distributing Cadre # programs (n
=18)% of
programs
Community health worker 5 27.8%
Traditional birth attendant 7 38.9%
Health workers/ANC providers 8 44.4%
Other (FP field worker, community drug keeper) 2 11.1%
36
Who administered the misoprostol?
Person Administering# programs (n
=18)% of
programs
Self-administered 11 61.1%
Traditional birth attendant 9 50.0%
Community health worker 1 5.6%
SBA or semi-skilled health worker 3 16.7%
37
Distribution rates: 21.0% – 96.6% % of women in target population who received misoprostol
Coverage rates: 16.2% – 93.8% % of women who delivered at home who used misoprostol
Only 10 of the 18 programs provided sufficient information to reliably calculate coverage rates
Measuring “Success”: Distribution and Coverage Rates
38
Distribution Timing Distributing Cadre Administration Method
ANC DistributionHome Visit
(late pregnancy)
At home birth
Comm-unity
health worker
Traditional birth
attendant
Health worker/
ANC provider
SelfTraditional
birth attendant
SBA or semi-skilled health worker
Any visit Late visit
Distribution Rate or Rate Range
22.5–49.1%
21.0–26.7%
54.5–96.6%
22.5–83.6%
54.5–96.6%
25.9–86.5%
21.0–49.1%
21.0–96.6%
25.9–86.5% 22.5%
Coverage Rate or Rate Range
16.8–65.9%
16.2–35.9% 55.7–93.8% 16.8–
73.5%87.9–93.8%
35.9–73.5%
16.2–65.9%
16.2–93.8%
35.9–73.5% 16.8%
Distribution & Coverage Rates by Implementation Strategy
Distribution of misoprostol by community workers (TBAs or CHWs) during home visits late in pregnancy achieved greatest distribution and coverage, potentially more than double the coverage achieved by programs where distribution was through health workers or as a part of ANC services.
39
Three programs (Nepal, Afghanistan and Zambia) reported the change in facility birth rate in program areas
Programs were not powered to measure a statistically significant change
In these three programs, facility birth rates increased in the target areas
No Adverse Change in Facility Birth Rates
40
Low Incidence of Adverse Outcomes
Outcomes # of occurrences
(total # of women taking misoprostol at home
births)
Frequency
(Range)
Administration Prior to Birth
7 (12 615) 0.06% (0%–0.23%)
Total Maternal Deaths 51 (86 732) 0.06% (0%–1.72%)
If programs want high coverage, they should design programs with population coverage in mind, considering: In-home distribution, by CHWs or TBAs, and Self-administration with adequate education & counseling.
Mistimed self-administration is rare and should not be a reason to limit program development.
Limited available data suggest that programs do not counter national strategies to promote facility-based births.Our review suggests that ANC-only distribution
achieves 50% less coverage, so it likely does not protect those who need coverage the most.